PBE - Invesco Dynamic Biotech & Genome ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
+0.02 (+0.03%)
At close: 3:44PM EDT
Stock chart is not supported by your current browser
Previous Close57.71
Bid0.00 x 1300
Ask0.00 x 900
Day's Range57.22 - 57.77
52 Week Range43.08 - 60.12
Avg. Volume19,979
Net Assets281.55M
PE Ratio (TTM)N/A
YTD Return21.84%
Beta (3y)1.63
Expense Ratio (net)0.59%
Inception Date2005-06-23
Trade prices are not sourced from all markets
  • What Analysts Recommend for Ionis after Q2 2018
    Market Realist8 days ago

    What Analysts Recommend for Ionis after Q2 2018

    Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017. Also, the company is estimated to report a net adjusted loss of $29.9 million during 2018 as compared to a net adjusted loss of $5.9 million during 2017, following the increase in selling, general, and administrative expenses as well as research and development expenses. The adjusted earnings per share for 2018 are estimated to come in at -$0.08 per share.

  • Analysts Are Bullish on Sarepta Therapeutics
    Market Realist10 days ago

    Analysts Are Bullish on Sarepta Therapeutics

    Wall Street analysts estimate Sarepta will report a net loss of $0.89 per share on revenues of $71.6 million in Q2 2018, which is more than a 100% YoY increase in revenues as compared to $35.0 million during the second quarter of 2017. Wall Street analyst estimates suggest the stock has the potential to return ~51.4% over the next 12 months. As of August 6, 19 analysts were tracking Sarepta Therapeutics stock.

  • Analysts Have Mixed Opinions about Ionis
    Market Realist11 days ago

    Analysts Have Mixed Opinions about Ionis

    What Do Analysts Expect from Ionis’s Second-Quarter Earnings? Wall Street analysts estimate that Ionis’s (IONS) Q2 2018 revenues will rise ~30.0% to $135.5 million as compared to $104.2 million in Q2 2017. Ionis’s stock price has decreased by nearly 14.5% over the last 12 months and decreased by ~14.3% in 2018 year-to-date.

  • ETF Trends17 days ago

    Biotech ETFs Rally as Illumina Tops Q2 Expectations

    Biotechnology sector ETFs were among the best performers Tuesday, with Illumina (ILMN) shares surging after the genomics firm beat second-quarter expectations and raised its year-end outlook. Among the best performing ETFs of Tuesday, the Invesco Dynamic Biotech & Genome (PBE) increased 3.0%, ARK Genomic Revolution Multi-Sector ETF (ARKG) advanced 2.5% and iShares Nasdaq Biotechnology ETF (IBB) rose 2.0%. Evercore analyst Ross Muken said in that the Illumina stock story is "far too compelling to ignore," reports Allison Gatlin for Investor's Business Daily.

  • Ionis Pharmaceuticals’ Valuation on May 23
    Market Realist3 months ago

    Ionis Pharmaceuticals’ Valuation on May 23

    Ionis Pharmaceuticals (IONS), a leading therapeutics company, develops and markets drugs for life-threatening diseases. The chart below compares Ionis’s revenue and EPS since Q1 2017. In the first quarter, Ionis’s revenue rose ~24.7% year-over-year to $144.4 million from $115.8 million.

  • How Ionis’s Spinraza Performed in 4Q17
    Market Realist5 months ago

    How Ionis’s Spinraza Performed in 4Q17

    How Ionis Pharmaceuticals Is Positioned in 2018

  • Exploring Ionis’s 3Q17 Quarterly Revenue Trend
    Market Realist7 months ago

    Exploring Ionis’s 3Q17 Quarterly Revenue Trend

    As we discussed earlier, Ionis Pharmaceuticals (IONS) is one of the leading biopharmaceutical companies focused on discovering, developing, and commercializing RNA-targeted (ribonucleic acid) therapies. Ionis has created a drug discovery platform and developed many drugs for the treatment of various life-threatening diseases through this broadly applicable platform. Ionis’s revenue sources include its commercial revenue, including its Spinraza royalties and licensing and royalty revenues, and its research and development revenue under its collaborative agreements.

  • Harvest Exchange11 months ago

    Gene-Editing Could Modify and Cure Disease: CRISPR vs. TALENs

    The following is original research by ARK's Genomic Revolution Analyst, Manisha Samy . Genome-Editing During the past decade, technology breakthroughs enabling the modification of complex genomes have changed the primary goal of research in ...

  • A Shot in the Arm for the UK Life Sciences Industry?
    Harvest Exchange11 months ago

    A Shot in the Arm for the UK Life Sciences Industry?

    Prime Minister May Looks to Bolster the Sector Earlier this year, Prime Minister Theresa May earmarked life sciences as one of five areas critical to the UK’s economic growth and commissioned a proposal on how to bolster the sector, especially as the ...

  • Market Realist11 months ago

    How Did Gilead’s Blockbuster Drug Harvoni Perform in 2Q17?

    Harvoni is the top-selling drug in Gilead Sciences’ (GILD) portfolio. The drug is used for the treatment of genotype-1 hepatitis C virus (or HCV) infection.

  • Market Realistlast year

    What’s Ionis Pharmaceuticals’ Valuation?

    Ionis Pharmaceuticals (IONS) has been one of the leading pharmaceutical companies in the RNA-targeted therapeutic space for over 26 years.